SEC Tracker
Get the app

Alaunos Therapeutics TCRT

Alaunos Therapeutics avoids delisting

Item 8.01 Other events

Form
8-K
Filed
Importance
Notable
  1. Received Nasdaq confirmation of compliance with stockholders equity requirement
  2. Hearing before Nasdaq Hearings Panel cancelled
  3. Private placement financing completed on Oct 14, 2026
  4. Common stock will continue trading on Nasdaq Capital Market

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Alaunos Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. BioCardia BCDA public float $10M, Jun 30, 2025
  2. Raphael Pharmaceutical RAPH public float $9M, Jun 30, 2025
  3. Traws Pharma ONTX public float $10M, Jun 30, 2025
  4. Mannatech MTEX public float $10M, Jun 30, 2025
  5. Bioxytran BIXT public float $9M, Jun 30, 2025